ReviewWorld journal of methodology2026
Fatty pancreas: Current insights and future perspectives.
Review in World journal of methodology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pancreatic Steatosis and Survival Outcomes in Pancreatic Ductal Adenocarcinoma: A Systematic Review of the Current Evidence.Diagnostics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the global increase in obesity rates, a newly emerging disease, non-alcoholic fatty pancreatic disease (NAFPD), has garnered increasing attention. The most important characteristic of NAFPD is fat accumulation in the pancreas in individuals with minimal alcohol consumption. However, the underlying pathogenesis remains poorly understood. This condition has been described using terms, such as fatty infiltration, fatty pancreas, or pancreatic steatosis. Similar to fat accumulation in the liver, known as metabolic dysfunction-associated steatotic liver disease (MASLD), fat can accumulate in other organs, including the pancreas. Therefore, MASLD and NAFPD have increasingly captured the attention of researchers and clinicians. However, precise quantification of pancreatic fat poses a significant challenge. Given the numerous challenges in diagnosing NAFPD and identifying its risk factors, pathogenesis, and clinical implications, extensive efforts have been made to understand its nature. This review highlights the recent advancements in NAFPD. Large-scale cohort studies and multicenter research efforts are anticipated to enhance our understanding of NAFPD, paving the way for improved early diagnosis, treatment, and exploration of its clinical associations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.